EA201900443A1 - Антитело к pd-l1 и его применение - Google Patents

Антитело к pd-l1 и его применение

Info

Publication number
EA201900443A1
EA201900443A1 EA201900443A EA201900443A EA201900443A1 EA 201900443 A1 EA201900443 A1 EA 201900443A1 EA 201900443 A EA201900443 A EA 201900443A EA 201900443 A EA201900443 A EA 201900443A EA 201900443 A1 EA201900443 A1 EA 201900443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fully human
antibodies
disclosed
affinity
lymphocytes
Prior art date
Application number
EA201900443A
Other languages
English (en)
Inventor
Ян Лавровский
Тинг Ксу
Сергей Барбашов
Алексей Репик
Михаил Самсонов
Василий Игнатьев
Шорена Арчуадзе
Original Assignee
Р-Фарм Оверсиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Р-Фарм Оверсиз Инк. filed Critical Р-Фарм Оверсиз Инк.
Publication of EA201900443A1 publication Critical patent/EA201900443A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрыты полностью человеческие антитела к PD-L1 и их соответствующие области применения. Полностью человеческие антитела способны к специфичному связыванию человеческого PD-L1. Антитела были получены путем применения метода скрининга на основе библиотеки дрожжевого дисплея, а также путем созревания аффинности для дополнительного улучшения их аффинности к PD-L1. Раскрытые полностью человеческие антитела к PD-L1 проявляют надлежащую специфичность, аффинность и стабильность. Они способны усиливать активность Т-лимфоцитов посредством связывания с активированными Т-лимфоцитами, при этом значительно ингибируя рост опухоли. Раскрытые полностью человеческие антитела к PD-L1 можно применять в диагностике и лечении PD-L1-связанных злокачественных новообразований и других сопутствующих заболеваний.
EA201900443A 2017-04-18 2018-04-18 Антитело к pd-l1 и его применение EA201900443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
EA201900443A1 true EA201900443A1 (ru) 2020-03-06

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201900443A EA201900443A1 (ru) 2017-04-18 2018-04-18 Антитело к pd-l1 и его применение

Country Status (16)

Country Link
US (1) US20210115143A1 (ru)
EP (1) EP3612565A4 (ru)
JP (2) JP2020517239A (ru)
KR (1) KR102323960B1 (ru)
CN (1) CN110856446A (ru)
AU (1) AU2018256392B2 (ru)
BR (1) BR112019021828B1 (ru)
CA (1) CA3059447A1 (ru)
CL (1) CL2019002953A1 (ru)
CO (1) CO2019012118A2 (ru)
EA (1) EA201900443A1 (ru)
MA (1) MA50038A (ru)
MX (1) MX2019012461A (ru)
PH (1) PH12019502302A1 (ru)
SG (1) SG11201909041SA (ru)
WO (1) WO2018195226A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
CN113677709A (zh) * 2019-04-11 2021-11-19 斯克里普斯抗体研究所 针对程序性细胞死亡蛋白配体-1(pd-l1)的抗体及其用途
MX2021004897A (es) * 2019-04-26 2021-06-18 I Mab Biopharma Us Ltd Anticuerpos pd-l1 humano.
US20210403568A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
PE20120341A1 (es) * 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
CA2926856A1 (en) * 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
US10835595B2 (en) * 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
CA2940242A1 (en) * 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
US10336824B2 (en) * 2015-03-13 2019-07-02 Cytomx Therapeutics, Inc. Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof
RU2770590C2 (ru) * 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Антитела против pd-l1 и их варианты

Also Published As

Publication number Publication date
WO2018195226A1 (en) 2018-10-25
AU2018256392B2 (en) 2024-05-16
MX2019012461A (es) 2019-12-11
CN110856446A (zh) 2020-02-28
PH12019502302A1 (en) 2020-09-21
MA50038A (fr) 2020-07-08
US20210115143A1 (en) 2021-04-22
KR102323960B1 (ko) 2021-11-10
BR112019021828A2 (pt) 2020-03-24
CA3059447A1 (en) 2018-10-25
EP3612565A4 (en) 2021-06-16
JP2023025003A (ja) 2023-02-21
EP3612565A1 (en) 2020-02-26
AU2018256392A1 (en) 2019-10-17
CO2019012118A2 (es) 2020-04-01
BR112019021828B1 (pt) 2022-09-20
JP2020517239A (ja) 2020-06-18
CL2019002953A1 (es) 2020-01-10
SG11201909041SA (en) 2019-11-28
KR20190141169A (ko) 2019-12-23

Similar Documents

Publication Publication Date Title
EA201900443A1 (ru) Антитело к pd-l1 и его применение
MX2023003418A (es) Moleculas multiespecificas de union a antigenos y usos de estas.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
EA201991214A1 (ru) Антитела против pd-1 и их композиции
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12020552229A1 (en) Il-11ra antibodies
EA201990171A1 (ru) Биспецифичное антитело против egfr и против cd3 и его применения
NZ704269A (en) Rspo3 binding agents and uses thereof
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
EA201491700A1 (ru) Человеческие антитела к cd27, методы и применение
MX2022012083A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
MX2018013008A (es) Anticuerpos st-2 humanos solubles y ensayos.
NZ612394A (en) Tnf-α binding proteins
EA201791393A3 (ru) Антитела к erbb3 и их применение
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201501061A1 (ru) Антитела к igf-1r с элиминированной способностью связываться с fcrn и их применение для лечения сосудистых глазных заболеваний
WO2015112895A3 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
EA202091974A1 (ru) Связывающие bcma антитела и их применение
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
BR112016023011A2 (pt) tratamento de câncer gástrico
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.